These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 32483737)

  • 21. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.
    Kubista B; Trieb K; Blahovec H; Kotz R; Micksche M
    Anticancer Res; 2002; 22(2A):789-92. PubMed ID: 12014651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
    Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
    Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Killers 2.0: NK cell therapies at the forefront of cancer control.
    Hodgins JJ; Khan ST; Park MM; Auer RC; Ardolino M
    J Clin Invest; 2019 Sep; 129(9):3499-3510. PubMed ID: 31478911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Potential of Natural Killer Cells in Gastric Cancer.
    Du Y; Wei Y
    Front Immunol; 2018; 9():3095. PubMed ID: 30719024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
    Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
    Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biology of natural killer cells and implications for therapy of human disease.
    Chiorean EG; Miller JS
    J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
    Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N
    Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells.
    Dianat-Moghadam H; Rokni M; Marofi F; Panahi Y; Yousefi M
    J Cell Physiol; 2018 Jan; 234(1):259-273. PubMed ID: 30144312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approaches to enhance natural killer cell cytotoxicity.
    Stenger TD; Miller JS
    Front Immunol; 2024; 15():1356666. PubMed ID: 38545115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulating natural killer cells to protect against cancer: recent developments.
    Gillgrass A; Ashkar A
    Expert Rev Clin Immunol; 2011 May; 7(3):367-82. PubMed ID: 21595603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of human natural killer cells for therapeutic use.
    Wagner AK; Alici E; Lowdell MW
    Cytotherapy; 2019 Mar; 21(3):315-326. PubMed ID: 30910383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.